Folger Nolan Fleming Douglas Capital Management Inc. Sells 1,366 Shares of Becton, Dickinson and Company (NYSE:BDX)

Folger Nolan Fleming Douglas Capital Management Inc. lessened its holdings in Becton, Dickinson and Company (NYSE:BDXFree Report) by 3.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 40,155 shares of the medical instruments supplier’s stock after selling 1,366 shares during the period. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $9,681,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of BDX. Oak Harvest Investment Services purchased a new stake in Becton, Dickinson and Company during the third quarter valued at approximately $2,791,000. Diversify Wealth Management LLC raised its holdings in Becton, Dickinson and Company by 18.4% during the 3rd quarter. Diversify Wealth Management LLC now owns 2,452 shares of the medical instruments supplier’s stock valued at $590,000 after buying an additional 381 shares during the period. Pinnacle Associates Ltd. lifted its position in Becton, Dickinson and Company by 0.7% in the third quarter. Pinnacle Associates Ltd. now owns 33,738 shares of the medical instruments supplier’s stock worth $8,226,000 after buying an additional 220 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its stake in Becton, Dickinson and Company by 135.2% during the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 22,936 shares of the medical instruments supplier’s stock worth $5,473,000 after buying an additional 13,186 shares during the period. Finally, AMI Asset Management Corp increased its position in Becton, Dickinson and Company by 39.8% during the third quarter. AMI Asset Management Corp now owns 322,209 shares of the medical instruments supplier’s stock valued at $77,685,000 after acquiring an additional 91,683 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Stifel Nicolaus upped their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James dropped their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Buy” and an average price target of $282.63.

Check Out Our Latest Stock Report on BDX

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $236.61 on Thursday. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The stock’s fifty day moving average price is $237.62 and its 200-day moving average price is $235.05. The firm has a market cap of $68.38 billion, a P/E ratio of 52.12, a P/E/G ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $259.92.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter last year, the firm posted $2.96 EPS. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, equities research analysts expect that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

See Also

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.